Leqvio

1 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANNEX I 
 

SUMMARY OF PRODUCT CHARACTERISTICS 



 

2 

This medicinal product is subject to additional monitoring. This will allow quick identification of 

new safety information. Healthcare professionals are asked to report any suspected adverse reactions. 

See section 4.8 for how to report adverse reactions. 

 

 

1. NAME OF THE MEDICINAL PRODUCT 
 

Leqvio 284 mg solution for injection in pre-filled syringe 

 

 

2. QUALITATIVE AND QUANTITATIVE COMPOSITION 
 

Each pre-filled syringe contains inclisiran sodium equivalent to 284 mg inclisiran in 1.5 ml solution. 

 

Each ml contains inclisiran sodium equivalent to 189 mg inclisiran. 

 

For the full list of excipients, see section 6.1. 

 

 

3. PHARMACEUTICAL FORM 
 

Solution for injection (injection). 

 

The solution is clear, colourless to pale yellow, and essentially free of particulates. 

 

 

4. CLINICAL PARTICULARS 
 

4.1 Therapeutic indications 
 

Leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and 

non-familial) or mixed dyslipidaemia, as an adjunct to diet: 

 in combination with a statin or statin with other lipid-lowering therapies in patients unable to 

reach LDL-C goals with the maximum tolerated dose of a statin, or 

 alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, 

or for whom a statin is contraindicated. 

 

4.2 Posology and method of administration 
 

Posology 

 

The recommended dose is 284 mg inclisiran administered as a single subcutaneous injection: initially, 

again at 3 months, followed by every 6 months. 

 

Missed doses 

If a planned dose is missed by less than 3 months, inclisiran should be administered and dosing 

continued according to the patient’s original schedule. 

 

If a planned dose is missed by more than 3 months, a new dosing schedule should be started – 

inclisiran should be administered initially, again at 3 months, followed by every 6 months. 

 

Treatment transition from monoclonal antibody PCSK9 inhibitors 

Inclisiran can be administered immediately after the last dose of a monoclonal antibody PCSK9 

inhibitor. To maintain LDL-C lowering it is recommended that inclisiran is administered within 

2 weeks after the last dose of a monoclonal antibody PCSK9 inhibitor. 

 



 

3 

Special populations 

Elderly (age ≥65 years) 

No dose adjustment is necessary in elderly patients. 

 

Hepatic impairment 

No dose adjustments are necessary for patients with mild (Child-Pugh class A) or moderate 

(Child-Pugh class B) hepatic impairment. No data are available in patients with severe hepatic 

impairment (Child-Pugh class C) (see section 5.2). Inclisiran should be used with caution in patients 

with severe hepatic impairment. 
 

Renal impairment 

No dose adjustments are necessary for patients with mild, moderate or severe renal impairment or 

patients with end-stage renal disease (see section 5.2). There is limited experience with inclisiran in 

patients with severe renal impairment. Inclisiran should be used with caution in these patients. See 

section 4.4 for precautions to take in case of haemodialysis. 

 

Paediatric population 

The safety and efficacy of inclisiran in children aged less than 18 years have not yet been established. 

No data are available. 

 

Method of administration 

 

Subcutaneous use. 

 

Inclisiran is for subcutaneous injection into the abdomen; alternative injection sites include the upper 

arm or thigh. Injections should not be given into areas of active skin disease or injury such as 

sunburns, skin rashes, inflammation or skin infections. 

 

Each 284 mg dose is administered using a single pre-filled syringe. Each pre-filled syringe is for 

single use only. 

 

Inclisiran is intended for administration by a healthcare professional. 

 

4.3 Contraindications 
 

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 

 

4.4 Special warnings and precautions for use 

 

Haemodialysis 

 

The effect of haemodialysis on inclisiran pharmacokinetics has not been studied. Considering that 

inclisiran is eliminated renally, haemodialysis should not be performed for at least 72 hours after 

inclisiran dosing. 

 

Sodium content 

 

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 

“sodium-free”. 

 



 

4 

4.5 Interaction with other medicinal products and other forms of interaction 
 

Inclisiran is not a substrate for common drug transporters and, although in vitro studies were not 

conducted, it is not anticipated to be a substrate for cytochrome P450. Inclisiran is not an inhibitor or 

inducer of cytochrome P450 enzymes or common drug transporters. Therefore, inclisiran is not 

expected to have clinically significant interactions with other medicinal products. Based on the limited 

data available, clinically meaningful interactions with atorvastatin, rosuvastatin or other statins are not 

expected. 

 

4.6 Fertility, pregnancy and lactation 
 

Pregnancy 

 

There are no or limited amount of data from the use of inclisiran in pregnant women. Animal studies 

do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). 

As a precautionary measure, it is preferable to avoid the use of inclisiran during pregnancy. 

 

Breast-feeding 

 

It is unknown whether inclisiran is excreted in human milk. Available pharmacodynamic/toxicological 

data in animals have shown excretion of inclisiran in milk (see section 5.3). A risk to newborns/infants 

cannot be excluded. 

 

A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from 

inclisiran therapy, taking into account the benefit of breast-feeding for the child and the benefit of 

therapy for the woman. 

 

Fertility 

 

No data on the effect of inclisiran on human fertility are available. Animal studies did not show any 

effects on fertility (see section 5.3). 

 

4.7 Effects on ability to drive and use machines 
 

Leqvio has no or negligible influence on the ability to drive and use machines. 

 

4.8 Undesirable effects 
 

Summary of the safety profile 

 

The only adverse reactions associated with inclisiran were adverse reactions at the injection site 

(8.2%). 

 

Tabulated list of adverse reactions 

 

Adverse reactions are presented by system organ class (Table 1). Frequency categories are defined as: 

very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 

to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from the available data). 

 

Table 1 Adverse reactions reported in patients treated with inclisiran 

 

System organ class Adverse reaction Frequency category 

General disorders and 

administration site conditions 

Adverse reactions at the 

injection site1 

Common 

1 See section “Description of selected adverse reactions” 

 



 

5 

Description of selected adverse reactions 

 

Adverse reactions at the injection site 

Adverse reactions at the injection site occurred in 8.2% and 1.8% of inclisiran and placebo patients, 

respectively, in the pivotal studies. The proportion of patients in each group who discontinued 

treatment due to adverse reactions at the injection site was 0.2% and 0.0%, respectively. All of these 

adverse reactions were mild or moderate in severity, transient and resolved without sequelae. The most 

frequently occurring adverse reactions at the injection site in patients treated with inclisiran were 

injection site reaction (3.1%), injection site pain (2.2%), injection site erythema (1.6%), and injection 

site rash (0.7%). 

 

Special populations 

 

Elderly 

Of the 1,833 patients treated with inclisiran in the pivotal studies, 981 (54%) were 65 years of age or 

older, while 239 (13%) were 75 years of age or older. No overall differences in safety were observed 

between these patients and younger patients. 

 

Immunogenicity 

 

In the pivotal studies 1,830 patients were tested for anti-drug antibodies. Confirmed positivity was 

detected in 1.8% (33/1,830) of patients prior to dosing and in 4.9% (90/1,830) of patients during the 

18 months of treatment with inclisiran. No clinically significant differences in the clinical efficacy, 

safety or pharmacodynamic profiles of inclisiran were observed in the patients who tested positive for 

anti-inclisiran antibodies. 

 

Laboratory values 

 

In the phase III clinical studies, there were more frequent elevations of serum hepatic transaminases 

between >1x the upper limit of normal (ULN) and ≤3x ULN in patients on inclisiran (ALT: 19.7% and 

AST: 17.2%) than in patients on placebo (ALT: 13.6% and AST: 11.1%). These elevations did not 

progress to exceed the clinically relevant threshold of 3x ULN, were asymptomatic and were not 

associated with adverse reactions or other evidence of liver dysfunction. 

 

Reporting of suspected adverse reactions 

 

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It 

allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare 

professionals are asked to report any suspected adverse reactions via the national reporting system 

listed in Appendix V. 

 

4.9 Overdose 
 

No clinically relevant adverse reactions were observed in healthy volunteers who received inclisiran at 

doses up to three times the therapeutic dose. No specific treatment for inclisiran overdose is available. 

In the event of an overdose, the patient should be treated symptomatically, and supportive measures 

instituted as required. 

 

 

http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc


 

6 

5. PHARMACOLOGICAL PROPERTIES 
 

5.1 Pharmacodynamic properties 
 

Pharmacotherapeutic group: lipid modifying agents, other lipid modifying agents, ATC code: 

C10AX16 

 

Mechanism of action 

 

Inclisiran is a cholesterol-lowering, double-stranded, small interfering ribonucleic acid (siRNA), 

conjugated on the sense strand with triantennary N-acetylgalactosamine (GalNAc) to facilitate uptake 

by hepatocytes. In hepatocytes, inclisiran utilises the RNA interference mechanism and directs 

catalytic breakdown of mRNA for proprotein convertase subtilisin kexin type 9. This increases LDL-C 

receptor recycling and expression on the hepatocyte cell surface, which increases LDL-C uptake and 

lowers LDL-C levels in the circulation. 

 

Pharmacodynamic effects 

 

Following a single subcutaneous administration of 284 mg inclisiran, LDL-C reduction was apparent 

within 14 days post-dose. Mean reductions of 48-51% for LDL-C were observed 30 to 60 days 

post-dose. At day 180, LDL-C levels were still reduced by approximately 53%. 

 

Clinical efficacy and safety 

 

In clinical studies and some publications, the 284 mg inclisiran dose is equivalent and referred to as 

300 mg inclisiran sodium salt. 

 

The efficacy of inclisiran was evaluated in three phase III studies in patients with atherosclerotic 

cardiovascular disease (ASCVD) (coronary heart disease, cerebrovascular disease or peripheral artery 

disease), ASCVD risk equivalents (type 2 diabetes mellitus, familial hypercholesterolaemia, or 

10-year risk of 20% or greater of having a cardiovascular event assessed by Framingham Risk Score 

or equivalent) and/or familial hypercholesterolaemia (FH). Patients were taking a maximally tolerated 

dose of statin with or without other lipid-modifying therapy and required additional LDL-C reduction 

(patients unable to reach their treatment goals). Approximately 17% of patients were statin intolerant. 

Patients were administered subcutaneous injections of 284 mg inclisiran or placebo on day 1, day 90, 

day 270 and day 450. Patients were followed until day 540. 

 

The effect of inclisiran on cardiovascular morbidity and mortality has not yet been determined. 

 

In the phase III pooled analysis, subcutaneously administered inclisiran lowered LDL-C between 50% 

and 55% as early as day 90 (Figure 1), which was maintained during long-term therapy. Maximal 

LDL-C reduction was achieved at day 150 following a second administration. Small but statistically 

significant increased LDL-C reductions up to 65% were associated with lower baseline LDL-C levels 

(approximately <2 mmol/l [77 mg/dl]), higher baseline PCSK9 levels and higher statin doses and 

statin intensity. 

 



 

7 

Figure 1 Mean percentage change from baseline LDL-C in patients with primary 

hypercholesterolaemia and mixed dyslipidaemia treated with inclisiran compared to 

placebo (pooled analysis) 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ASCVD and ASCVD risk equivalents 

Two studies were conducted in patients with ASCVD and ASCVD risk equivalents (ORION-10 and 

ORION-11). Patients were taking a maximally tolerated dose of statins with or without other 

lipid-modifying therapy, such as ezetimibe, and required additional LDL-C reduction. As lowering 

LDL-C is expected to improve cardiovascular outcomes, the co-primary endpoints in each study were 

the percentage change in LDL-C from baseline to day 510 relative to placebo and the time-adjusted 

percentage change in LDL-C from baseline after day 90 and up to day 540 to estimate the integrated 

effect on LDL-C over time. 

 

ORION-10 was a multicentre, double-blind, randomised, placebo-controlled 18-month study 

conducted in 1,561 patients with ASCVD. 

 

The mean age at baseline was 66 years (range: 35 to 90 years), 60% were ≥65 years old, 31% were 

women, 86% were White, 13% were Black, 1% were Asian and 14% were Hispanic or Latino 

ethnicity. The mean baseline LDL C was 2.7 mmol/l (105 mg/dl). Sixty-nine percent (69%) were 

taking high-intensity statins, 19% were taking medium-intensity statins, 1% were taking low-intensity 

statins and 11% were not on a statin. The most commonly administered statins were atorvastatin and 

rosuvastatin. 

 

Inclisiran significantly reduced the mean percentage change in LDL-C from baseline to day 510 

compared to placebo by 52% (95% CI: -56%, -49%; p <0.0001) (Table 2). 

 

Inclisiran also significantly reduced the time-adjusted percentage change in LDL-C from baseline after 

day 90 and up to day 540 by 54% compared to placebo (95% CI: -56%, -51%; p <0.0001). For 

additional results, see Table 2. 

 

Inclisiran Placebo 
M

e
a
n
 p

e
rc

e
n
ta

g
e
 c

h
a
n
g
e
 f
ro

m
 b

a
s
e
lin

e
 

No. of patients 
Placebo 

Inclisiran 



 

8 

Table 2 Mean percentage change from baseline and difference from placebo in lipid 

parameters at day 510 in ORION-10 

 

Treatment group LDL-C Total 

cholesterol 

Non-HDL-C Apo-B Lp(a)* 

Mean baseline 

value in mg/dl** 

105 181 134 94 122 

Day 510 (mean percentage change from baseline) 

Placebo (n=780) 1 0 0 -2 4 

Inclisiran (n=781) -51 -34 -47 -45 -22 

Difference from 

placebo (LS mean) 

(95% CI) 

-52 

(-56, -49) 

-33 

(-35, -31) 

-47 

(-50, -44) 

-43 

(-46, -41) 

-26 

(-29, -22) 

*At day 540; median percentage change in Lp(a) values 

**Mean baseline value in nmol/l for Lp(a) 

 

At day 510, the LDL-C target of <1.8 mmol/l (70 mg/dl) was achieved by 84% of inclisiran patients 

with ASCVD compared to 18% of placebo patients. 

 

Consistent and statistically significant (p<0.0001) reductions in percentage change in LDL-C from 

baseline to day 510 and time-adjusted percentage change in LDL-C from baseline after day 90 and up 

to day 540 were observed across all subgroups irrespective of baseline demographics, baseline disease 

characteristics (including gender, age, body mass index, race and baseline statin use), comorbidities 

and geographic regions. 

 

ORION-11 was an international, multicentre, double-blind, randomised, placebo-controlled 18-month 

study which evaluated 1,617 patients with ASCVD or ASCVD risk equivalents. More than 75% of 

patients were receiving a high-intensity statin background treatment, 87% of patients had ASCVD and 

13% were ASCVD risk equivalent. 

 

The mean age at baseline was 65 years (range: 20 to 88 years), 55% were ≥65 years old, 28% were 

women, 98% were White, 1% were Black ,1% were Asian and 1% were Hispanic or Latino ethnicity. 

The mean baseline LDL-C was 2.7 mmol/l (105 mg/dl). Seventy-eight percent (78%) were taking 

high-intensity statins, 16% were taking medium-intensity statins, 0.4% were taking low-intensity 

statins and 5% were not on a statin. The most commonly administered statins were atorvastatin and 

rosuvastatin. 

 
Inclisiran significantly reduced the mean percentage change in LDL-C from baseline to day 510 

compared to placebo by 50% (95% CI: -53%, -47%; p<0.0001) (Table 3). 

 

Inclisiran also significantly reduced time-adjusted percentage change in LDL-C from baseline after 

day 90 and up to day 540 by 49% compared to placebo (95% CI: -52%, -48%; p<0.0001). For 

additional results, see Table 3. 

 



 

9 

Table 3 Mean percentage change from baseline and difference from placebo in lipid 

parameters at day 510 in ORION-11 

 

Treatment group LDL-C Total 

cholesterol 

Non-HDL-C Apo-B Lp(a)* 

Mean baseline 

value in mg/dl** 

105 185 136 96 107 

Day 510 (mean percentage change from baseline) 

Placebo (n=807) 4 2 2 1 0 

Inclisiran (n=810) -46 -28 -41 -38 -19 

Difference from 

placebo (LS mean) 

(95% CI) 

-50 

(-53, -47) 

-30 

(-32, -28) 

-43 

(-46, -41) 

-39 

(-41, -37) 

-19 

(-21, -16) 

*At day 540; median percentage change in Lp(a) values 

**Mean baseline value in nmol/l for Lp(a) 

 

At day 510, the LDL-C target of <1.8 mmol/l (70 mg/dl) was achieved by 82% of inclisiran patients 

with ASCVD compared to 16% of placebo patients. In patients with an ASCVD risk equivalent, the 

LDL-C target of <2.6 mmol/l (100 mg/dl) was achieved by 78% of inclisiran patients compared to 

31% of placebo patients. 

 

Consistent and statistically significant (p<0.05) percentage change in LDL-C from baseline to day 510 

and time-adjusted percentage change in LDL-C from baseline after day 90 and up to day 540 was 

observed across all subgroups irrespective of baseline demographics, baseline disease characteristics 

(including gender, age, body mass index, race and baseline statin use), comorbidities, and geographic 

regions. 

 

Heterozygous familial hypercholesterolaemia 

ORION-9 was an international, multicentre, double-blind, randomised, placebo-controlled 18-month 

trial in 482 patients with heterozygous familial hypercholesterolaemia (HeFH). All patients were 

taking maximally tolerated doses of statins with or without other lipid-modifying therapy, such as 

ezetimibe, and required additional LDL-C reduction. The diagnosis of HeFH was made either by 

genotyping or clinical criteria (“definite FH” using either the Simon Broome or WHO/Dutch Lipid 

Network criteria). 

 

The co-primary endpoints were the percentage change in LDL-C from baseline to day 510 relative to 

placebo, and the time-adjusted percentage change in LDL-C from baseline after day 90 and up to 

day 540 to estimate the integrated effect on LDL-C over time. Key secondary endpoints were the 

absolute change in LDL-C from baseline to day 510, the time-adjusted absolute change in LDL-C 

from baseline after day 90 and up to day 540 and the percentage change from baseline to day 510 in 

PCSK9, total cholesterol, Apo-B, and non-HDL-C. Additional secondary endpoints included the, 

individual responsiveness to inclisiran and the proportion of patients attaining global lipid targets for 

their level of ASCVD risk. 

 

The mean age at baseline was 55 years (range: 21 to 80 years), 22% were ≥65 years old, 53% were 

women, 94% were White, 3% were Black, 3% were Asian and 3% were Hispanic or Latino ethnicity. 

The mean baseline LDL-C was 4.0 mmol/l (153 mg/dl). Seventy-four percent (74%) were taking 

high-intensity statins, 15% were taking medium-intensity statins and 10% were not on a statin. 

Fifty-two percent (52%) of patients were treated with ezetimibe. The most commonly administered 

statins were atorvastatin and rosuvastatin. 

 
Inclisiran significantly reduced the mean percentage change in LDL-C from baseline to day 510 

compared to placebo by 48% (95% CI: -54%, -42%; p<0.0001) (Table 4). 

 

Inclisiran also significantly reduced the time-adjusted percentage change in LDL-C from baseline after 

day 90 and up to day 540 by 44% compared to placebo (95% CI: -48%, -40%; p<0.0001). For 

additional results, see Table 4. 



 

10 

 

Table 4 Mean percentage change from baseline and difference from placebo in lipid 

parameters at day 510 in ORION-9 

 

Treatment group LDL-C Total 

cholesterol 

Non-HDL-C Apo-B Lp(a)* 

Mean baseline 

value in mg/dl** 

153 231 180 124 121 

Day 510 (mean percentage change from baseline) 

Placebo (n=240) 8 7 7 3 4 

Inclisiran (n=242) -40 -25 -35 -33 -13 

Difference from 

placebo (LS mean) 

(95% CI) 

-48 

(-54, -42) 

-32 

(-36, -28) 

-42 

(-47, -37) 

-36 

(-40, -32) 

-17 

(-22, -12) 

*At day 540; median percentage change in Lp(a) values 

**Mean baseline value in nmol/l for Lp(a) 

 

At day 510, 52.5% of inclisiran patients with ASCVD achieved their LDL-C target of <1.8 mmol/l 

(70 mg/dl) compared to 1.4% of placebo patients with ASCVD, while in the group with ASCVD risk 

equivalents 66.9% of inclisiran patients achieved their LDL-C target of <2.6 mmol/l (100 mg/dl) 

compared to 8.9% of placebo patients. 

 

Consistent and statistically significant (p<0.05) percentage change in LDL-C from baseline to day 510 

and time-adjusted percentage change in LDL-C from baseline after day 90 and up to day 540 were 

observed across all subgroups irrespective of baseline demographics, baseline disease characteristics 

(including gender, age, body mass index, race and baseline statin use), comorbidities, and geographic 

regions. 

 

Paediatric population 

 

The European Medicines Agency has deferred the obligation to submit the results of studies with 

inclisiran in one or more subsets of the paediatric population in the treatment of elevated cholesterol 

(see section 4.2 for information on paediatric use). 

 

5.2 Pharmacokinetic properties 

 

Absorption 

 

Following single subcutaneous administration, systemic exposure to inclisiran increased 

approximately dose-proportionally over a range from 24 mg to 756 mg. At the recommended dosing 

regimen of 284 mg plasma concentrations reached peak in approximately 4 hours post dose, with a 

mean Cmax of 509 ng/ml. Concentrations reached undetectable levels within 48 hours post dosing. The 

mean area under the plasma concentration-time curve from dosing extrapolated to infinity was 

7980 ng*h/ml. Pharmacokinetic findings following multiple subcutaneous administrations of inclisiran 

were similar to single-dose administration. 

 

Distribution 

 

Inclisiran is 87% protein bound in vitro at the relevant clinical plasma concentrations. Following a 

single subcutaneous 284 mg dose of inclisiran to healthy adults, the apparent volume of distribution is 

approximately 500 litres. Based on non-clinical data inclisiran has been shown to have high uptake 

into and selectivity for the liver, the target organ for cholesterol lowering. 

 



 

11 

Biotransformation 

 

Inclisiran is primarily metabolised by nucleases to shorter inactive nucleotides of varying length. 

Inclisiran is not a substrate for common drug transporters and, although in vitro studies were not 

conducted, it is not anticipated to be a substrate for cytochrome P450. 

 

Elimination 

 

The terminal elimination half-life of inclisiran is approximately 9 hours and no accumulation occurs 

with multiple dosing. Sixteen percent (16%) of inclisiran is cleared through the kidney. 

 

Linearity/non-linearity 

 

In the phase I clinical study, an approximately dose proportional increase in inclisiran exposure was 

observed after administration of subcutaneous doses of inclisiran ranging from 24 mg to 756 mg. No 

accumulation and no time-dependent changes were observed after multiple subcutaneous doses of 

inclisiran. 

 

Pharmacokinetic/pharmacodynamic relationship(s) 

 

In the phase I clinical study, a dissociation was observed between inclisiran pharmacokinetic 

parameters and LDL-C pharmacodynamic effects. Selective delivery of inclisiran to hepatocytes, 

where it is incorporated into the RNA-induced silencing complex (RISC), results in a long duration of 

action, beyond that anticipated based on the plasma elimination half-life of 9 hours. The maximal 

effects of reducing LDL-C were observed with a 284 mg dose, with higher doses not producing 

greater effects. 

 

Special populations 

 

Renal impairment 

Pharmacokinetic analysis of data from a dedicated renal impairment study reported an increase in 

inclisiran Cmax of approximately 2.3, 2.0 and 3.3-fold and an increase in inclisiran AUC of 

approximately 1.6, 1.8 and 2.3-fold, in patients with mild (creatinine clearance [CrCL] of 60 ml/min to 

89 ml/min), moderate (CrCL of 30 ml/min to 59 ml/min) and severe (CrCL of 15 ml/min to 

29 ml/min) renal impairment, respectively, relative to patients with normal renal function. Despite the 

higher transient plasma exposures over 48 hours, the reduction in LDL-C was similar across all groups 

of renal function. Based on population pharmacodynamic modelling, no dose adjustment is 

recommended in patients with end-stage renal disease. Based on pharmacokinetic, pharmacodynamic 

and safety assessments, no dose adjustment is necessary in patients with mild, moderate or severe 

renal impairment. The effect of haemodialysis on inclisiran pharmacokinetics has not been studied. 

Considering that inclisiran is eliminated renally, haemodialysis should not be performed for at least 

72 hours after Leqvio dosing. 

 

Hepatic impairment 

Pharmacokinetic analysis of data from a dedicated hepatic impairment study reported an increase in 

inclisiran Cmax of approximately 1.1 and 2.1-fold, and an increase in inclisiran AUC of 

approximately1.3 and 2.0-fold, respectively, in patients with mild (Child-Pugh class A) and moderate 

(Child-Pugh class B) hepatic impairment relative to patients with normal hepatic function. Despite the 

higher transient inclisiran plasma exposures, the reductions in LDL-C were similar between the groups 

of patients administered inclisiran with normal hepatic function and mild hepatic impairment. In 

patients with moderate hepatic impairment baseline PCSK9 levels were markedly lower and the 

reduction in LDL-C was less than that observed in patients with normal hepatic function. No dose 

adjustment is necessary in patients with mild to moderate hepatic impairment (Child-Pugh class A and 

B). Leqvio has not been studied in patients with severe hepatic impairment (Child-Pugh class C). 

 



 

12 

Other special populations 

A population pharmacodynamic analysis was conducted on data from 4,328 patients. Age, body 

weight, gender, race, and creatinine clearance were not found to significantly influence inclisiran 

pharmacodynamics. No dose adjustments are recommended for patients with these demographics. 

 

5.3 Preclinical safety data 
 

In repeated dose toxicology studies conducted in rats and monkeys the no observed adverse effect 

levels (NOAEL) were identified as the highest doses administered subcutaneously which produced 

exposures considerably in excess of the maximum human exposure. Microscopic observations from 

toxicology studies included vacuolation in hepatocytes of rats and lymph node macrophages of 

monkeys, and the presence of basophilic granules in hepatocytes of monkeys and kidneys of rats and 

monkeys. These observations were not associated with changes in clinical laboratory parameters and 

are not considered adverse. 

 

Inclisiran was not carcinogenic in Sprague-Dawley rats or in TgRasH2 mice administered inclisiran at 

doses sufficiently in excess of clinical doses. 

 

No mutagenic or clastogenic potential of inclisiran was found in a battery of tests, including  a 

bacterial mutagenicity assay, in vitro chromosomal aberration assay in human peripheral blood 

lymphocytes and an in vivo rat bone marrow micronucleus assay. 

 

Reproduction studies performed in rats and rabbits have revealed no evidence of harm to the foetus 

due to inclisiran at the highest doses administered, which produced exposure considerably in excess of 

the maximum human exposure. 

 

Inclisiran did not affect the fertility or reproductive performance of male rats and female rats exposed 

to inclisiran prior to gestation and during gestation. The doses were associated with systemic 

exposures many times greater than the human exposure at clinical doses. 

 

Inclisiran has been observed in the milk of lactating rats; however, there is no evidence of systemic 

absorption in suckling rat neonates. 

 

 

6. PHARMACEUTICAL PARTICULARS 

 

6.1 List of excipients 
 

Water for injections 

Sodium hydroxide (for pH adjustment) 

Concentrated phosphoric acid(for pH adjustment) 

 

6.2 Incompatibilities 
 

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal 

products. 

 

6.3 Shelf life 
 

2 years 

 

6.4 Special precautions for storage 

 

This medicinal product does not require any special storage conditions. Do not freeze. 

 



 

13 

6.5 Nature and contents of container 

 

1.5 ml solution in a pre-filled syringe (Type I glass) with plunger stopper (bromobutyl, fluorotec 

coated rubber) with needle and rigid needle shield. 

 

Pack size of one pre-filled syringe. 

 

6.6 Special precautions for disposal 
 

Leqvio should be inspected visually prior to administration. The solution should be clear, colourless to 

pale yellow and essentially free of particulates. If the solution contains visible particulate matter, the 

solution should not be used. 

 

Any unused medicinal product or waste material should be disposed of in accordance with local 

requirements. 

 

 

7. MARKETING AUTHORISATION HOLDER 
 

Novartis Europharm Limited 

Vista Building 

Elm Park, Merrion Road 

Dublin 4 

Ireland 

 

 

8. MARKETING AUTHORISATION NUMBER(S) 

 

EU/1/20/1494/001 

 

 

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 

 

 

10. DATE OF REVISION OF THE TEXT 

 

 

Detailed information on this medicinal product is available on the website of the European Medicines 

Agency http://www.ema.europa.eu 
  

http://www.ema.europa.eu/


 

14 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANNEX II 
 

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH 

RELEASE 

 

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY 

AND USE 

 

C. OTHER CONDITIONS AND REQUIREMENTS OF THE 

MARKETING AUTHORISATION 

 

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO 

THE SAFE AND EFFECTIVE USE OF THE MEDICINAL 

PRODUCT 



 

15 

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 
 

Name and address of the manufacturer(s) responsible for batch release 

 

APO-CARE Pharma GmbH 

Hauptstrasse 198 

33647 Bielefeld 

Nordrhein-Westfalen 

Germany 

 

 

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 

 

Medicinal product subject to medical prescription. 

 

 

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING 

AUTHORISATION 

 

 Periodic safety update reports (PSURs) 

 

The requirements for submission of PSURs for this medicinal product are set out in the list of 

Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC 

and any subsequent updates published on the European medicines web-portal. 

 

The marketing authorisation holder (MAH) shall submit the first PSUR for this product within 

6 months following authorisation. 

 

 

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND 

EFFECTIVE USE OF THE MEDICINAL PRODUCT 

 

 Risk management plan (RMP) 

 

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance 

activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the 

marketing authorisation and any agreed subsequent updates of the RMP. 

 

An updated RMP should be submitted: 

 At the request of the European Medicines Agency; 

 Whenever the risk management system is modified, especially as the result of new information 

being received that may lead to a significant change to the benefit/risk profile or as the result of 

an important (pharmacovigilance or risk minimisation) milestone being reached. 

  



 

16 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANNEX III 

 

LABELLING AND PACKAGE LEAFLET 

  



 

17 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

A. LABELLING 
  



 

18 

 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 

 

PRE-FILLED SYRINGE CARTON 

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

Leqvio 284 mg solution for injection in pre-filled syringe 

inclisiran 

 

 

2. STATEMENT OF ACTIVE SUBSTANCE(S) 

 

Each pre-filled syringe contains inclisiran sodium equivalent to 284 mg inclisiran in 1.5 ml solution. 

Each ml contains inclisiran sodium equivalent to 189 mg inclisiran. 

 

 

3. LIST OF EXCIPIENTS 

 

Also contains: water for injections, sodium hydroxide and concentrated phosphoric acid. See leaflet 

for further information. 

 

 

4. PHARMACEUTICAL FORM AND CONTENTS 

 

Solution for injection 

 

1 pre-filled syringe 

 

 

5. METHOD AND ROUTE(S) OF ADMINISTRATION 

 

Read the package leaflet before use. 

Subcutaneous use. 

 

 

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE SIGHT AND REACH OF CHILDREN 

 

Keep out of the sight and reach of children. 

 

 

7. OTHER SPECIAL WARNING(S), IF NECESSARY 

 

 

8. EXPIRY DATE 

 

EXP 

 

 

9. SPECIAL STORAGE CONDITIONS 

 

Do not freeze. 

 



 

19 

 

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 

APPROPRIATE 

 

 

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 

 

Novartis Europharm Limited 

Vista Building 

Elm Park, Merrion Road 

Dublin 4 

Ireland 

 

 

12. MARKETING AUTHORISATION NUMBER(S) 

 

EU/1/20/1494/001 

 

 

13. BATCH NUMBER 

 

Lot 

 

 

14. GENERAL CLASSIFICATION FOR SUPPLY 

 

 

15. INSTRUCTIONS ON USE 

 

 

16. INFORMATION IN BRAILLE 

 

Justification for not including Braille accepted. 

 

 

17. UNIQUE IDENTIFIER – 2D BARCODE 

 

2D barcode carrying the unique identifier included. 

 

 

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA 

 

PC 

SN 

NN 

  



 

20 

 

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS 

 

PRE-FILLED SYRINGE BLISTER FOIL 

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

Leqvio 284 mg solution for injection in pre-filled syringe 

inclisiran 

 

 

2. NAME OF THE MARKETING AUTHORISATION HOLDER 

 

Novartis Europharm Limited 

 

 

3. EXPIRY DATE 

 

EXP 

 

 

4. BATCH NUMBER 

 

Lot 

 

 

5. OTHER 

  



 

21 

 

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 

 

PRE-FILLED SYRINGE LABEL 

 

 

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION 

 

Leqvio 284 mg injection 

inclisiran 

SC 

 

 

2. METHOD OF ADMINISTRATION 

 

 

3. EXPIRY DATE 

 

EXP 

 

 

4. BATCH NUMBER 

 

Lot 

 

 

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 

 

1.5 ml 

 

 

6. OTHER 

  



 

22 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

B. PACKAGE LEAFLET 



 

23 

Package leaflet: Information for the patient 
 

Leqvio 284 mg solution for injection in pre-filled syringe 

inclisiran 

 

This medicine is subject to additional monitoring. This will allow quick identification of new 

safety information. You can help by reporting any side effects you may get. See the end of section 4 

for how to report side effects. 

 

Read all of this leaflet carefully before you are given this medicine because it contains important 

information for you. 
- Keep this leaflet. You may need to read it again. 

- If you have any further questions, ask your doctor, pharmacist or nurse. 

- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible 

side effects not listed in this leaflet. See section 4. 

 

What is in this leaflet 

 

1. What Leqvio is and what it is used for 

2. What you need to know before you are given Leqvio 

3. How Leqvio is given 

4. Possible side effects 

5. How to store Leqvio 

6. Contents of the pack and other information 

 

 

1. What Leqvio is and what it is used for 

 

What Leqvio is and how it works 

Leqvio contains the active substance inclisiran. Inclisiran lowers levels of LDL-cholesterol (“bad” 

cholesterol), which can cause heart and blood circulation problems when levels are raised. 

 

Inclisiran works by interfering with RNA (genetic material in body cells) to limit the production of a 

protein called PCSK9. This protein can increase LDL-cholesterol levels and preventing its production 

helps to lower your LDL-cholesterol levels. 

 

What Leqvio is used for 

Leqvio is used in addition to your cholesterol-lowering diet if you are an adult with a high cholesterol 

level in your blood (primary hypercholesterolaemia, including heterozygous familial and non-familial, 

or mixed dyslipidaemia). 

 

Leqvio is given: 

- together with a statin (a type of medicine that treats high cholesterol), sometimes combined with 

another cholesterol-lowering treatment if the maximum dose of the statin does not work well 

enough, or 

- alone or together with other cholesterol-lowering medicines when statins do not work well or 

cannot be used. 

 

 

2. What you need to know before you are given Leqvio 

 

You must not be given Leqvio 
- if you are allergic to inclisiran or any of the other ingredients of this medicine (listed in 

section 6). 

 



 

24 

Warnings and precautions 

Talk to your doctor, pharmacist or nurse before you are given Leqvio: 

- if you are receiving dialysis 

- if you have severe liver disease 

- if you have severe kidney disease 

 

Children and adolescents 

Do not give this medicine to children and adolescents under 18 years of age, because there is no 

experience of using the medicine in this age group. 

 

Other medicines and Leqvio 
Tell your doctor, pharmacist or nurse if you are using, have recently used or might use any other 

medicines. 

 

Pregnancy and breast-feeding 

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 

your doctor, pharmacist or nurse for advice before you are given this medicine. 

 

The use of Leqvio should be avoided during pregnancy. 

 

It is not yet known whether Leqvio passes into human breast milk. Your doctor will help you to decide 

whether to continue breast-feeding or to start treatment with Leqvio. Your doctor will consider the 

potential benefits of treatment for you, compared with the health benefits and risks of breast-feeding 

for your baby. 

 

Driving and using machines 
Leqvio is not expected to affect your ability to drive or use machines. 

 

Leqvio contains sodium 

This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 

“sodium-free”. 
 

 

3. How Leqvio is given 

 

The recommended dose of Leqvio is 284 mg given by injection under the skin (subcutaneous 

injection). The next dose is given after 3 months, followed by further doses every 6 months. 

 

Before starting Leqvio you should be on a diet to lower your cholesterol and it is likely that you will 

be taking a statin. You should stay on this cholesterol-lowering diet and keep taking the statin all the 

time you receive Leqvio. 

 

Leqvio is for injection under the skin of the abdomen; alternative injection sites include the upper arm 

or thigh. Leqvio will be given to you by a doctor, pharmacist or nurse (healthcare professional). 

 

If you receive more Leqvio than you should 
This medicine will be given to you by your doctor, pharmacist or nurse (healthcare professional). In 

the highly unlikely event that you are given too much (an overdose) the doctor or other healthcare 

professional will check you for side effects. 

 

If you miss your dose of Leqvio 

If you miss your appointment for your Leqvio injection, contact your doctor, pharmacist or nurse as 

soon as you can to arrange your next injection. 

 

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 

 

 



 

25 

4. Possible side effects 
 

Like all medicines, this medicine can cause side effects, although not everybody gets them. 

 

Common (may affect up to 1 in 10 people) 

 Injection site reactions, such as pain, redness or rash. 

 
Reporting of side effects 

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 

effects not listed in this leaflet. You can also report side effects directly via the national reporting 

system listed in Appendix V. By reporting side effects you can help provide more information on the 

safety of this medicine. 

 

 

5. How to store Leqvio 

 

Keep this medicine out of the sight and reach of children. 

 

Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The 

expiry date refers to the last day of that month. 

 

This medicine does not require any special storage conditions. Do not freeze. 

 

The doctor, pharmacist or nurse will check this medicine and will discard it if it contains particles. 

 

Medicines should not be disposed of via wastewater or household waste. Your doctor, pharmacist or 

nurse will throw away medicines no longer being used. These measures will help protect the 

environment. 

 

 

6. Contents of the pack and other information 

 

What Leqvio contains 

 The active substance is inclisiran. Each pre-filled syringe contains inclisiran sodium equivalent 

to 284 mg inclisiran in 1.5 ml solution. Each ml contains inclisiran sodium equivalent to 189 mg 

inclisiran. 

 The other ingredients are water for injections, sodium hydroxide (see section 2 “Leqvio contains 

sodium”) and concentrated phosphoric acid. 

 

What Leqvio looks like and contents of the pack 

Leqvio is a clear, colourless to pale yellow solution, essentially free of particulates. 

 

Each pack contains one single-use pre-filled syringe. 

 

Marketing Authorisation Holder 

Novartis Europharm Limited 

Vista Building 

Elm Park, Merrion Road 

Dublin 4 

Ireland 

 

Manufacturer 

APO-CARE Pharma GmbH 

Hauptstrasse 198 

33647 Bielefeld 

Nordrhein-Westfalen 

Germany 

http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc


 

26 

 

For any information about this medicine, please contact the local representative of the Marketing 

Authorisation Holder: 

 

België/Belgique/Belgien 

Novartis Pharma N.V. 

Tél/Tel: +32 2 246 16 11 

 

Lietuva 

SIA Novartis Baltics Lietuvos filialas 

Tel: +370 5 269 16 50 

 

България 

Novartis Bulgaria EOOD 

Тел.: +359 2 489 98 28 

 

Luxembourg/Luxemburg 

Novartis Pharma N.V. 

Tél/Tel: +32 2 246 16 11 

 

Česká republika 

Novartis s.r.o. 

Tel: +420 225 775 111 

 

Magyarország 

Novartis Hungária Kft. 

Tel.: +36 1 457 65 00 

Danmark 

Novartis Healthcare A/S 

Tlf: +45 39 16 84 00 

 

Malta 

Novartis Pharma Services Inc. 

Tel: +356 2122 2872 

Deutschland 

Novartis Pharma GmbH 

Tel: +49 911 273 0 

 

Nederland 

Novartis Pharma B.V. 

Tel: +31 88 04 52 111 

Eesti 

SIA Novartis Baltics Eesti filiaal 

Tel: +372 66 30 810 

 

Norge 

Novartis Norge AS 

Tlf: +47 23 05 20 00 

Ελλάδα 

Novartis (Hellas) A.E.B.E. 

Τηλ: +30 210 281 17 12 

 

Österreich 

Novartis Pharma GmbH 

Tel: +43 1 86 6570 

España 

Novartis Farmacéutica, S.A. 

Tel: +34 93 306 42 00 

 

Polska 

Novartis Poland Sp. z o.o. 

Tel.: +48 22 375 4888 

France 

Novartis Pharma S.A.S. 

Tél: +33 1 55 47 66 00 

 

Portugal 
Novartis Farma - Produtos Farmacêuticos, S.A. 

Tel: +351 21 000 8600 

Hrvatska 

Novartis Hrvatska d.o.o. 

Tel. +385 1 6274 220 

 

România 

Novartis Pharma Services Romania SRL 

Tel: +40 21 31299 01 

Ireland 

Novartis Ireland Limited 

Tel: +353 1 260 12 55 

 

Slovenija 

Novartis Pharma Services Inc. 

Tel: +386 1 300 75 50 

Ísland 

Vistor hf. 

Sími: +354 535 7000 

 

Slovenská republika 

Novartis Slovakia s.r.o. 

Tel: +421 2 5542 5439 

 

Italia 

Novartis Farma S.p.A. 

Tel: +39 02 96 54 1 

Suomi/Finland 

Novartis Finland Oy 

Puh/Tel: +358 (0)10 6133 200 

 



 

27 

Κύπρος 

Novartis Pharma Services Inc. 

Τηλ: +357 22 690 690 

 

Sverige 

Novartis Sverige AB 

Tel: +46 8 732 32 00 

 

Latvija 

SIA Novartis Baltics 

Tel: +371 67 887 070 

 

United Kingdom 

Novartis Pharmaceuticals UK Ltd. 

Tel: +44 1276 698370 

 
 

This leaflet was last revised in 
 

 

Other sources of information 

Detailed information on this medicine is available on the European Medicines Agency web site: 

http://www.ema.europa.eu 

  

http://www.ema.europa.eu/


 

28 

The following information is intended for healthcare professionals only: 

 

Leqvio 284 mg solution for injection in pre-filled syringe 

inclisiran 

 

Healthcare professionals should refer to the Summary of Product Characteristics for full prescribing 

information. 

 

Indication (see section 4.1 of the SmPC) 

 

Leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and 

non-familial) or mixed dyslipidaemia, as an adjunct to diet: 

 in combination with a statin or statin with other lipid-lowering therapies in patients unable to 

reach LDL-C goals with the maximum tolerated dose of a statin, or 

 alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, 

or for whom a statin is contraindicated. 

 

Posology (see section 4.2 of the SmPC) 
 

The recommended dose is 284 mg inclisiran administered as a single subcutaneous injection: initially, 

again at 3 months, followed by every 6 months. 

 

Missed doses 

If a planned dose is missed by less than 3 months, inclisiran should be administered and dosing 

continued according to the patient’s original schedule. 

 

If a planned dose is missed by more than 3 months, a new dosing schedule should be started – 

inclisiran should be administered initially, again at 3 months, followed by every 6 months. 

 

Treatment transition from monoclonal antibody PCSK9 inhibitors 

Inclisiran can be administered immediately after the last dose of a monoclonal antibody PCSK9 

inhibitor. To maintain LDL-C lowering it is recommended that inclisiran is administered within 

2 weeks after the last dose of a monoclonal antibody PCSK9 inhibitor. 

 

Special populations 

Elderly (age ≥65 years) 

No dose adjustment is necessary in elderly patients. 

 

Hepatic impairment 

No dose adjustments are necessary for patients with mild (Child-Pugh class A) or moderate 

(Child-Pugh class B) hepatic impairment. No data are available in patients with severe hepatic 

impairment (Child-Pugh class C). Inclisiran should be used with caution in patients with severe 

hepatic impairment. 
 

Renal impairment 

No dose adjustments are necessary for patients with mild, moderate or severe renal impairment or 

patients with end stage renal disease. There is limited experience wth inclisiran in patients with severe 

renal impairment. Inclisiran should be used with caution in these patients. See section 4.4 of the SmPC 

for precautions to take in case of haemodialysis. 

 

Paediatric population 

The safety and efficacy of inclisiran in children aged less than 18 years has not yet been established. 

No data are available. 

 



 

29 

Method of administration (see section 4.2 of the SmPC) 

 

Subcutaneous use. 

 

Inclisiran is for subcutaneous injection into the abdomen; alternative injection sites include the upper 

arm or thigh. Injections should not be given into areas of active skin disease or injury such as 

sunburns, skin rashes, inflammation, or skin infections. 

 

Each 284 mg dose is administered using a single pre-filled syringe. Each pre-filled syringe is for 

single use only. 

 

Inclisiran is intended for administration by a healthcare professional. 

 

Contraindications (see section 4.3 of the SmPC) 

 

Hypersensitivity to the active substance or to any of the excipients. 

 

Special warnings and precautions (see section 4.4 of the SmPC) 

 

Haemodialysis 

 

The effect of haemodialysis on inclisiran pharmacokinetics has not been studied. Considering that 

inclisiran is eliminated renally, haemodialysis should not be performed for at least 72 hours after 

inclisiran dosing. 

 

Storage (see section 6.4 of the SmPC) 

 

This medicinal product does not require any special storage conditions. Do not freeze. 

 


	SUMMARY OF PRODUCT CHARACTERISTICS
	A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
	B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
	C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
	D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
	A. LABELLING
	B. PACKAGE LEAFLET